Targeting Exogenous Proteins to Mitochondria - Del Gaizo Moore, Victoria
35,99 €
inkl. MwSt.
Versandkostenfrei*
Versandfertig in 1-2 Wochen
payback
18 °P sammeln
  • Broschiertes Buch

Defects in mitochondrial function are responsible for many human diseases. Two major problems have hindered gene therapy of mitochondria defects: 1) Mitochondria are in all tissues of the body so a gene therapy must be capable of reaching all tissues. 2) The therapy must localize specifically to mitochondria. Using a short peptide sequence derived from the HIV genome, called TAT, the hypothesis that TAT fusion proteins could cross both mitochondrial membranes and incorporation of a mitochondrial signal sequence (MTS) into a TAT fusion protein would allow processing and localization of…mehr

Andere Kunden interessierten sich auch für
Produktbeschreibung
Defects in mitochondrial function are responsible for many human diseases. Two major problems have hindered gene therapy of mitochondria defects: 1) Mitochondria are in all tissues of the body so a gene therapy must be capable of reaching all tissues. 2) The therapy must localize specifically to mitochondria. Using a short peptide sequence derived from the HIV genome, called TAT, the hypothesis that TAT fusion proteins could cross both mitochondrial membranes and incorporation of a mitochondrial signal sequence (MTS) into a TAT fusion protein would allow processing and localization of exogenous proteins in mitochondria was tested. Using isolated mitochondria, cultured cells, animals, and model membranes, TAT-MTS proteins rapidly transduces into large unilamellar vesicles, cells and mitochondria, and persisted over time in vitro and in vivo. TAT-MTS fusion proteins will be a useful tool in understanding mitochondrial function as well as the development of mitochondrial protein therapies.
Hinweis: Dieser Artikel kann nur an eine deutsche Lieferadresse ausgeliefert werden.
Autorenporträt
Victoria Del Gaizo Moore received her PhD in Molecular Medicine from Wake Forest University School of Medicine in 2004. She then completed a postdoctoral fellowship with Anthony Letai, MD, PhD at Dana-Farber Cancer Institute, Harvard Medical School in 2009. Currently she is an Assistant Professor in the Chemistry Department at Elon University.